Florida committee advances kratom regulation PCS after heated debate and mixed testimony

Representative Black pressed a proposed committee substitute for House Bill 1205 on kratom regulation, saying it aims to replace patchwork oversight with a uniform framework that protects consumers and children. The PCS would require Department of Health certification of laboratories that test kratom, set limits on product strength, require specific packaging and labeling, restrict sales to locations that bar persons under 21, regulate online sales and create penalties and enforcement mechanisms, including seizure under the Florida Contraband Forfeiture Act.

The proposal follows an emergency rule from the Florida Attorney General that temporarily placed products with more than 400 parts per million of 7‑hydroxy‑mitragynine (7‑OH) on the state Schedule I list; Representative Black said that rule is temporary and that the PCS covers a broader portion of the market. He described public‑safety concerns grounded in sample testing and overdose data, telling the committee that ‘‘we've had over 500 deaths over the last 10 years’’ and that the industry exceeds ‘‘more than 1 and a half billion dollars.’’ The PCS would cap 7‑OH in products to 2% and prohibit adulteration or synthetic concentrates, sponsor Black said.

Proponent witnesses urged strong action. Cynthia West, a substance‑abuse counselor and mother, described clinical experience with patients who combine kratom with methadone or buprenorphine and recounted her son’s addiction to stronger kratom products; she said the measure ‘‘will save lives’’ and urged the committee to pass the bill. Barney Bishop of the Florida Smart Justice Alliance cited FDA warnings, the risk of contamination (lead, salmonella) and the uncertain safety profile of kratom.

Industry testimony pushed back. Joseph Petri of the Kava and Kratom Retailers Association said kratom is a botanical distinct from lab‑synthesized 7‑OH and cited Johns Hopkins researcher Jack E. Henningfield to argue mitragynine and kratom ‘‘are not considered opioids’’; Petri urged lawmakers to work with the industry on targeted regulation rather than a broad bill that, in his view, conflates separate issues.

Members asked technical questions about metabolism and testing. Representative Henson sought clarification on whether mitragynine converts in the human body to 7‑OH; the sponsor said published estimates of metabolic conversion vary (he cited figures in the ~20–30% range) and that the PCS addresses those conversion risks by setting product limits and banning adulterants. Representative Overdorf raised enforcement and threshold‑evasion concerns tied to laboratory detection and manufacturing.

After debate and the sponsor’s closing remarks — in which he said he would continue to work with stakeholders and could support a ban if regulation proved ineffective — the committee took a roll‑call vote. The clerk recorded 17 yeas and 0 nays; the chair announced the PCS would be reported favorably to the next stage.

The measure now moves forward with opportunities for sponsors and industry representatives to propose specific language changes and technical clarifications; no floor schedule was announced at the committee meeting.